Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 | Q09470 | 10/20 | 1.00 |
| ▸ | KCNAB1 | Q14722 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945005 | 0.89 | KCNA1 (0.92) | KCNA1KCNAB1NPC1RAB9ANLRP3 | |
| SCHEMBL1945507 | 0.88 | KCNA1 (1.00) | KCNA1KCNAB1NPC1RAB9ANLRP3 | |
| SCHEMBL1945684 | 0.88 | KCNA1 (0.80) | KCNA1KCNAB1NPC1RAB9ANLRP3 | |
| SCHEMBL1945192 | 0.82 | KCNA1 (0.92) | KCNA1KCNAB1NPC1RAB9ANLRP3 | |
| SCHEMBL1947206 | 0.82 | KCNA1 (1.00) | KCNA1KCNAB1NPC1RAB9ANLRP3 | |
| SCHEMBL1944620 | 0.82 | KCNA1 (0.80) | KCNA1KCNAB1NPC1RAB9AALDH1A1 | |
| SCHEMBL1945000 | 0.82 | KCNA1 (1.00) | KCNA1KCNAB1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1948073 | 0.81 | KCNA1 (1.00) | KCNA1KCNAB1NLRP3ALDH1A1HPGD | |
| SCHEMBL1945019 | 0.81 | KCNA1 (1.00) | KCNA1KCNAB1NPC1RAB9AALDH1A1 | |
| SCHEMBL1946654 | 0.80 | KCNA1 (0.84) | KCNA1KCNAB1NPC1RAB9ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | claimed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-2066317-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | Lectus Therapeutics Limited (GB) | 2009-06-10 | — | — | EP | claimed |
| WO-2008038051-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | claimed |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-2069309-A1 | ION CHANNEL MODULATORS&USES THEREOF | Lectus Therapeutics Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066317-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | Lectus Therapeutics Limited (GB) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038051-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038053-A1 | ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038053-A1 | ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | KCNH3, KCNN3, KCNH2 | KCNA1 26/4885KCNAB1 40/4885NPC1 2041/4885 |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | HCAR2, HCAR1, SCN7A | KCNA1 167/4885KCNAB1 98/4885NPC1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.